Discovery of a Novel Series of Inhibitors of Lymphoid Tyrosine Phosphatase with Activity in Human T Cells

Article de journal


Auteurs / Editeurs


Domaines de Recherche

Pas d'articles correspondants trouvés.


Détails sur la publication

Liste des auteurs: Stanford SM, Krishnamurthy D, Falk MD, Messina R, Debnath B, Li S, Liu T, Kazemi R, Dahl R, He YT, Yu XA, Chan AC, Zhang ZY, Barrios AM, Woods VL, Neamati N, Bottini N
Editeur: American Chemical Society
Année de publication: 2011
Numéro du volume: 54
Numéro de publication: 6
Page d'accueil: 1640
Dernière page: 1654
Nombre de pages: 15
ISSN: 0022-2623
Languages: Anglais-Royaume-Uni (EN-GB)


Résumé

The lymphoid tyrosine phosphatase LYP, encoded by the PTPN22 gene, is a critical regulator of signaling in T cells and recently emerged as a candidate target for therapy of autoimmune diseases. Here, by library screening, we identified a series of noncompetitive inhibitors of LYP that showed activity in primary T cells. Kinetic analysis confirmed that binding of the compounds to the phosphatase is nonmutually exclusive with respect to a known bidentate competitive inhibitor. The mechanism of action of the lead inhibitor compound 4e was studied by a combination of hydrogen/deuterium-exchange mass spectrometry and molecular modeling. The results suggest that the inhibitor interacts critically with a hydrophobic patch located outside the active site of the phosphatase. Targeting of secondary allosteric sites is viewed as a promising yet unexplored approach to develop pharmacological inhibitors of protein tyrosine phosphatases. Our novel scaffold could be a starting point to attempt development of "nonactive site" anti-LYP pharmacological agents.


Mots-clés

Pas d'articles correspondants trouvés.


Documents

Pas d'articles correspondants trouvés.

Dernière mise à jour le 2019-23-08 à 11:15